BACKGROUND: Serological assessments for human onchocerciasis are based on IgG4 reactivity against the OV-16 antigen, with sensitivities of 60-80%. We have previously identified 7 novel proteins that could improve serodiagnosis. METHODS: IgG4 responses to these 7 proteins were assessed by luciferase immunoprecipitation (LIPS) and enzyme-linked immunosorbent (ELISA) immunoassays. RESULTS: OVOC10469 and OVOC3261 were identified as the most promising candidates by IgG4-based immunoassays with sensitivities of 53% for rOVOC10469 and 78% for rOVOC3261 while specificity for each was >99%. These 2 antigens in combination with OV-16 increased the sensitivity for patent infections to 94%. The kinetics of appearance of these IgG4 responses based on experimentally infected non-human primates indicated that they were microfilarial- driven. Further, the IgG4 responses to both OVOC10469 and OVOC3261 (as well as to OV-16) drop significantly (p<0.05) following successful treatment for onchocerciasis. A prototype lateral flow rapid diagnostic test to detect IgG4 to both Ov-16 and OVOC3261 was developed and tested demonstrating an overall 94% sensitivity. CONCLUSION: The combined use of rOVOC3261 with OV-16 improved serologic assessment of O. volvulus infection, a current unmet need toward the goal of elimination of transmission of O. volvulus. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Serological assessments for human onchocerciasis are based on IgG4 reactivity against the OV-16 antigen, with sensitivities of 60-80%. We have previously identified 7 novel proteins that could improve serodiagnosis. METHODS: IgG4 responses to these 7 proteins were assessed by luciferase immunoprecipitation (LIPS) and enzyme-linked immunosorbent (ELISA) immunoassays. RESULTS: OVOC10469 and OVOC3261 were identified as the most promising candidates by IgG4-based immunoassays with sensitivities of 53% for rOVOC10469 and 78% for rOVOC3261 while specificity for each was >99%. These 2 antigens in combination with OV-16 increased the sensitivity for patent infections to 94%. The kinetics of appearance of these IgG4 responses based on experimentally infected non-human primates indicated that they were microfilarial- driven. Further, the IgG4 responses to both OVOC10469 and OVOC3261 (as well as to OV-16) drop significantly (p<0.05) following successful treatment for onchocerciasis. A prototype lateral flow rapid diagnostic test to detect IgG4 to both Ov-16 and OVOC3261 was developed and tested demonstrating an overall 94% sensitivity. CONCLUSION: The combined use of rOVOC3261 with OV-16 improved serologic assessment of O. volvulus infection, a current unmet need toward the goal of elimination of transmission of O. volvulus. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: M L Eberhard; J W Dickerson; A E Boyer; V C Tsang; R Zea-Flores; E M Walker; F O Richards; G Zea-Flores; E Strobert Journal: Am J Trop Med Hyg Date: 1991-02 Impact factor: 2.345
Authors: Karla R Feeser; Vitaliano Cama; Jeffrey W Priest; Elizabeth A Thiele; Ryan E Wiegand; Thomson Lakwo; Sindew M Feleke; Paul T Cantey Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345
Authors: Peter D Burbelo; Roshan Ramanathan; Amy D Klion; Michael J Iadarola; Thomas B Nutman Journal: J Clin Microbiol Date: 2008-05-28 Impact factor: 5.948
Authors: Roshan Ramanathan; Peter D Burbelo; Sandra Groot; Michael J Iadarola; Franklin A Neva; Thomas B Nutman Journal: J Infect Dis Date: 2008-08-01 Impact factor: 5.226
Authors: Mario A Rodríguez-Pérez; Nadia A Fernández-Santos; María E Orozco-Algarra; José A Rodríguez-Atanacio; Alfredo Domínguez-Vázquez; Kristel B Rodríguez-Morales; Olga Real-Najarro; Francisco G Prado-Velasco; Eddie W Cupp; Frank O Richards; Hassan K Hassan; Jesús F González-Roldán; Pablo A Kuri-Morales; Thomas R Unnasch Journal: PLoS Negl Trop Dis Date: 2015-07-10
Authors: Yvonne L Lont; Luc E Coffeng; Sake J de Vlas; Allison Golden; Tala de Los Santos; Gonzalo J Domingo; Wilma A Stolk Journal: PLoS Negl Trop Dis Date: 2017-01-23
Authors: Rodney Ogwang; Dennis Muhanguzi; Kioko Mwikali; Ronald Anguzu; Joe Kubofcik; Thomas B Nutman; Mark Taylor; Charles R Newton; Angela Vincent; Andrea L Conroy; Kevin Marsh; Richard Idro Journal: Epilepsia Open Date: 2021-03-12
Authors: Saskia I Johanns; Richard G Gantin; Bawoubadi Wangala; Kossi Komlan; Wemboo A Halatoko; Meba Banla; Potchoziou Karabou; Adrian Jf Luty; Hartwig Schulz-Key; Carsten Köhler; Peter T Soboslay Journal: PLoS Negl Trop Dis Date: 2022-05-03
Authors: Robert Colebunders; Wilma A Stolk; Joseph Nelson Siewe Fodjo; Charles D Mackenzie; Adrian Hopkins Journal: Infect Dis Poverty Date: 2019-10-03 Impact factor: 4.520
Authors: Ole Lagatie; Emmanuel Njumbe Ediage; Dirk Van Roosbroeck; Stijn Van Asten; Ann Verheyen; Linda Batsa Debrah; Alex Debrah; Maurice R Odiere; Ruben T'Kindt; Emmie Dumont; Koen Sandra; Lieve Dillen; Tom Verhaeghe; Rob Vreeken; Filip Cuyckens; Lieven J Stuyver Journal: PLoS Negl Trop Dis Date: 2021-11-29
Authors: Alvin Pumelele Ndondo; Brian Eley; Jo Madeleine Wilmshurst; Angelina Kakooza-Mwesige; Maria Pia Giannoccaro; Hugh J Willison; Pedro M Rodríguez Cruz; Jeannine M Heckmann; Kathleen Bateman; Angela Vincent Journal: Front Immunol Date: 2022-03-09 Impact factor: 7.561
Authors: Rodney Ogwang; Albert Ningwa; Pamela Akun; Paul Bangirana; Ronald Anguzu; Rajarshi Mazumder; Noriko Salamon; Oliver Johannes Henning; Charles R Newton; Catherine Abbo; Amos Deogratius Mwaka; Kevin Marsh; Richard Idro Journal: Front Neurol Date: 2021-06-03 Impact factor: 4.003